

Elekta and Azra AI announce partnership to enhance cancer registry operations with AIpowered automation

Collaboration between Azra AI and Elekta will boost cancer registry workflow efficiency, reduce manual data entry, and set the stage for future advancements

SAN JOSE, Calif., – Elekta (EKTA-B.ST) announced today that it has partnered with <u>Azra AI</u>, the industry's only end-to-end oncology workflow automation platform, to enhance cancer registry operations through automation and AI-powered data management.

This partnership combines Azra Al's real-time patient identification and workflow automation with Elekta's next-generation cancer registry software, Elekta ONE Registry Informatics*. The combined technologies will enable cancer registry teams to automate cancer casefinding, streamline data ingestion, increase reporting accuracy, and ensure compliance with national and international standards.

"Cancer registries are essential for improving cancer care outcomes," says Anish Patankar, Elekta's SVP & Head of Business Line Software. "By bringing together Elekta's advanced registry software and Azra AI's AI-driven workflow automation, we are helping hospitals advance data integrity and optimize operations. This strategic collaboration is also setting the stage for future technological advancements, benefiting oncology data specialists, hospitals and their patients."

John Marshall, CEO of Azra AI, adds: "Healthcare and cancer centers are under increasing pressure to modernize and streamline registry reporting while maintaining accuracy and compliance. Through this partnership, we are providing oncology teams with advanced tools to enhance efficiency, reduce administrative burden, and improve patient outcomes."

Elekta ONE Registry Informatics, hosted on Axis Cloud, offers a secure, web-based platform designed to optimize cancer registry workflows, improve abstracting, and ensure compliance with American College of Surgeons, North American Association of Central Cancer Registries (NAACCR), Surveillance, Epidemiology, and End Results (SEER), and other regulatory bodies.

Learn more about the partnership at the <u>National Cancer Registrars Association (NCRA) Annual</u> <u>Education Conference</u>, May 3-6 in Orlando at Elekta booth # 205, 207, 209.

*Elekta ONE Registry Informatics may not be available in all markets.

###

For further information, please contact:

Mattias Thorsson, Vice President, Head of Corporate Communications Tel: +46 70 865 8012, e-mail: <u>Mattias.Thorsson@elekta.com</u> Time zone: CET: Central European Time

Raven Canzeri, Global Director, Media Relations Tel: +1 770-670-2524, e-mail: <u>Raven.Canzeri@elekta.com</u>



Time zone: ET: Eastern Time

About Elekta

As a leader in precision radiation therapy, Elekta is committed to ensuring every patient has access to the best cancer care possible. We openly collaborate with customers to advance sustainable, outcome-driven and cost-efficient solutions to meet evolving patient needs, improve lives and bring hope to everyone dealing with cancer. To us, it's personal, and our global team of 4,700 employees combine passion, science, and imagination to profoundly change cancer care. We don't just build technology, we build hope. Elekta is headquartered in Stockholm, Sweden, with offices in more than 40 countries and listed on Nasdaq Stockholm. For more information, visit <u>elekta.com</u>.